drugset / Trial / NCT01945593
BAX 855 Continuation
Phase 3
Completed
218 enrolled
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire · collab
Non-randomizedParallel-groupOpen-labelPrevention
Summary
To continue the evaluation of the safety and efficacy of BAX 855 for prophylaxis and treatment of bleeding episodes in adult and pediatric previously treated patients (PTPs) aged ≤ 75 years of age with severe hemophilia A.
Timeline
- Start
- 2013-10-15
- Primary completion
- 2018-03-02
- Completion
- 2018-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT | Protein / enzyme biologic | 45 iu/kg | — |
| Subject | ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT | Protein / enzyme biologic | 80 iu/kg | — |